These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 38997273)

  • 1. High frequency electrical stimulation reduces α-synuclein levels and α-synuclein-mediated autophagy dysfunction.
    George J; Shafiq K; Kapadia M; Kalia LV; Kalia SK
    Sci Rep; 2024 Jul; 14(1):16091. PubMed ID: 38997273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of alpha-synuclein oligomers in preclinical models of Parkinson's disease by electrical stimulation in vitro and deep brain stimulation in vivo.
    Lee EJ; Aguirre-Padilla DH; Fomenko A; Pawar G; Kapadia M; George J; Lozano AM; Hamani C; Kalia LV; Kalia SK
    Brain Stimul; 2024; 17(2):166-175. PubMed ID: 38342364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma exosomes impair microglial degradation of α-synuclein through V-ATPase subunit V1G1.
    Li Y; Wang Y; Kou L; Yin S; Chi X; Sun Y; Wu J; Jin Z; Zhou Q; Zou W; Wang T; Xia Y
    CNS Neurosci Ther; 2024 May; 30(5):e14738. PubMed ID: 38702933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin L prevents the accumulation of alpha-synuclein fibrils in the cell.
    Matsuki A; Watanabe Y; Hashimoto S; Hoshino A; Matoba S
    Genes Cells; 2024 Apr; 29(4):328-336. PubMed ID: 38366711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
    Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH
    Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetramethylpyrazine Analogue T-006 Promotes the Clearance of Alpha-synuclein by Enhancing Proteasome Activity in Parkinson's Disease Models.
    Zhou H; Shao M; Guo B; Li C; Lu Y; Yang X; ShengnanLi ; Li H; Zhu Q; Zhong H; Wang Y; Zhang Z; Lu J; Lee SM
    Neurotherapeutics; 2019 Oct; 16(4):1225-1236. PubMed ID: 31313223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation.
    Cai CZ; Zhou HF; Yuan NN; Wu MY; Lee SM; Ren JY; Su HX; Lu JJ; Chen XP; Li M; Tan JQ; Lu JH
    Phytomedicine; 2019 Aug; 61():152842. PubMed ID: 31048127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E46K Mutant α-Synuclein Is Degraded by Both Proteasome and Macroautophagy Pathway.
    Yan JQ; Yuan YH; Chu SF; Li GH; Chen NH
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30388770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct alpha-Synuclein species induced by seeding are selectively cleared by the Lysosome or the Proteasome in neuronally differentiated SH-SY5Y cells.
    Pantazopoulou M; Brembati V; Kanellidi A; Bousset L; Melki R; Stefanis L
    J Neurochem; 2021 Mar; 156(6):880-896. PubMed ID: 32869336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific Knockdown of α-Synuclein by Peptide-Directed Proteasome Degradation Rescued Its Associated Neurotoxicity.
    Qu J; Ren X; Xue F; He Y; Zhang R; Zheng Y; Huang H; Wang W; Zhang J
    Cell Chem Biol; 2020 Jun; 27(6):751-762.e4. PubMed ID: 32359427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein.
    Yu WH; Dorado B; Figueroa HY; Wang L; Planel E; Cookson MR; Clark LN; Duff KE
    Am J Pathol; 2009 Aug; 175(2):736-47. PubMed ID: 19628769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMPK-dependent autophagy activation and alpha-Synuclein clearance: a putative mechanism behind alpha-mangostin's neuroprotection in a rotenone-induced mouse model of Parkinson's disease.
    Parekh P; Sharma N; Sharma M; Gadepalli A; Sayyed AA; Chatterjee S; Kate A; Khairnar A
    Metab Brain Dis; 2022 Dec; 37(8):2853-2870. PubMed ID: 36178640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted degradation of ⍺-synuclein aggregates in Parkinson's disease using the AUTOTAC technology.
    Lee J; Sung KW; Bae EJ; Yoon D; Kim D; Lee JS; Park DH; Park DY; Mun SR; Kwon SC; Kim HY; Min JO; Lee SJ; Suh YH; Kwon YT
    Mol Neurodegener; 2023 Jun; 18(1):41. PubMed ID: 37355598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-synuclein suppresses microglial autophagy and promotes neurodegeneration in a mouse model of Parkinson's disease.
    Tu HY; Yuan BS; Hou XO; Zhang XJ; Pei CS; Ma YT; Yang YP; Fan Y; Qin ZH; Liu CF; Hu LF
    Aging Cell; 2021 Dec; 20(12):e13522. PubMed ID: 34811872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson's disease models through PKA activation.
    Chen JY; Zhu Q; Cai CZ; Luo HB; Lu JH
    Phytomedicine; 2022 Jul; 101():154125. PubMed ID: 35525236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Synuclein Intermediates α-Synuclein Neurotoxicity in Parkinson's Disease.
    Xian M; Li J; Liu T; Hou K; Sun L; Wei J
    ACS Chem Neurosci; 2024 Jul; 15(13):2445-2453. PubMed ID: 38905183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuronal Bmi-1 is critical for melatonin induced ubiquitination and proteasomal degradation of α-synuclein in experimental Parkinson's disease models.
    Srivastava AK; Choudhury SR; Karmakar S
    Neuropharmacology; 2021 Aug; 194():108372. PubMed ID: 33157086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.
    Lewis KA; Yaeger A; DeMartino GN; Thomas PJ
    J Bioenerg Biomembr; 2010 Feb; 42(1):85-95. PubMed ID: 20148295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn).
    Batelli S; Peverelli E; Rodilossi S; Forloni G; Albani D
    Neuroscience; 2011 Nov; 195(4):128-37. PubMed ID: 21906659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.